Literature DB >> 20302960

Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia.

Michael R Verneris1, Mary Eapen, Reggie Duerst, Paul A Carpenter, Michael J Burke, B V Afanasyev, Morton J Cowan, Wensheng He, Robert Krance, Chi-Kong Li, Poh-Lin Tan, John E Wagner, Stella M Davies.   

Abstract

Reduced-intensity conditioning regimens have been used extensively in adults with hematologic malignancies. To address whether this is a feasible approach for children with acute lymphoblastic leukemia, we evaluated transplant outcomes in 38 recipients transplanted from 1995-2005 for whom this was their first transplant. The median age at transplant was 12 years, and 47% had performance scores <90%. Disease status was first complete remission (CR) in 13%, > or =CR2 in 60% of patients, and 22% had active disease at transplantation. Matched related donors were available for a third of patients, about half of whom received bone marrow (BM) and the others, peripheral blood progenitor cells. Sixty percent of unrelated donor transplant recipients received peripheral blood progenitor cells. The day-100 probability of grade II-IV acute graft-versus-host disease was 37% and the 3-year probability of chronic graft-versus-host disease, 26%. At 3 years, the probability of treatment-related mortality was 40%, relapse 37%, and disease-free survival 30%. These data indicate long-term DFS can be achieved using reduced-intensity conditioning regimens in children with acute lymphoblastic leukemia. Given the relatively small cohort, these findings must be validated in a larger population. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20302960      PMCID: PMC2904410          DOI: 10.1016/j.bbmt.2010.03.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  26 in total

1.  Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.

Authors:  G J Ruiz-Argüelles; D Gómez-Almaguer; A Ruiz-Argüelles; O González-Llano; O G Cantú; J C Jaime-Pérez
Journal:  Am J Hematol       Date:  2001-04       Impact factor: 10.047

2.  Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.

Authors:  F Locatelli; M Zecca; R Rondelli; F Bonetti; G Dini; A Prete; C Messina; C Uderzo; M Ripaldi; F Porta; G Giorgiani; E Giraldi; A Pession
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

3.  Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

Authors:  M Michallet; K Bilger; F Garban; M Attal; A Huyn; D Blaise; N Milpied; P Moreau; P Bordigoni; M Kuentz; A Sadoun; J Y Cahn; G Socié; X Thomas; P Arnaud; N Raus; V Lhéritier; A Pigneux; J M Boiron
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

4.  Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.

Authors:  A Bacigalupo; M T Van Lint; D Occhini; F Gualandi; T Lamparelli; G Sogno; E Tedone; F Frassoni; J Tong; A M Marmont
Journal:  Blood       Date:  1991-04-01       Impact factor: 22.113

5.  Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease.

Authors:  R Arnold; G Massenkeil; M Bornhäuser; G Ehninger; D W Beelen; A A Fauser; U Hegenbart; B Hertenstein; A D Ho; W Knauf; H J Kolb; K Kolbe; H G Sayer; R Schwerdtfeger; H Wandt; D Hoelzer
Journal:  Leukemia       Date:  2002-12       Impact factor: 11.528

6.  Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.

Authors:  P Bader; T Klingebiel; A Schaudt; U Theurer-Mainka; R Handgretinger; P Lang; D Niethammer; J F Beck
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

7.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

8.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation.

Authors:  K Atkinson; M M Horowitz; R P Gale; D W van Bekkum; E Gluckman; R A Good; N Jacobsen; H J Kolb; A A Rimm; O Ringdén
Journal:  Blood       Date:  1990-06-15       Impact factor: 22.113

9.  Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.

Authors:  Rodrigo Martino; Sergio Giralt; María Dolores Caballero; Stephen Mackinnon; Paolo Corradini; Francesc Fernández-Avilés; Jesús San Miguel; Jorge Sierra
Journal:  Haematologica       Date:  2003-05       Impact factor: 9.941

Review 10.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

View more
  9 in total

1.  Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.

Authors:  Liusheng Huang; Patricia Lizak; Francesca Aweeka; Janel Long-Boyle
Journal:  J Pharm Biomed Anal       Date:  2013-08-23       Impact factor: 3.935

2.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

3.  Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.

Authors:  Orly R Klein; Jessica Buddenbaum; Noah Tucker; Allen R Chen; Christopher J Gamper; David Loeb; Elias Zambidis; Nicolas J Llosa; Jeffrey S Huo; Nancy Robey; Mary Jo Holuba; Yvette L Kasamon; Shannon R McCurdy; Richard Ambinder; Javier Bolaños-Meade; Leo Luznik; Ephraim J Fuchs; Richard J Jones; Kenneth R Cooke; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-22       Impact factor: 5.742

4.  Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission.

Authors:  Eneida R Nemecek; Kristin Ellis; Wensheng He; Nancy J Bunin; Rajinder S Bajwa; Alexandra Cheerva; Mitchell S Cairo; Christopher Dvorak; Michel Duval; Stella Davies; Mary Eapen; Thomas G Gross; Ayad A Hussein; Margaret L MacMillan; Parinda A Mehta; Michael A Pulsipher; Adriana Seber; Ann E Woolfrey; Haydar A Frangoul; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-27       Impact factor: 5.742

5.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

6.  Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

Authors:  Menachem Bitan; Wensheng He; Mei-Jie Zhang; Hisham Abdel-Azim; Mouhab Fakhreddine Ayas; Bella Bielorai; Paul A Carpenter; Mitchell S Cairo; Miguel Angel Diaz; John T Horan; Sonata Jodele; Carrie L Kitko; Kirk R Schultz; Morris Kletzel; Kimberly A Kasow; Leslie E Lehmann; Parinda A Mehta; Nirali Shah; Michael A Pulsipher; Tim Prestidge; Adriana Seber; Shalini Shenoy; Ann E Woolfrey; Lolie C Yu; Stella M Davies
Journal:  Blood       Date:  2014-01-16       Impact factor: 22.113

7.  Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia.

Authors:  James Tracey; Mei-Jie Zhang; Elizabeth Thiel; Kathleen A Sobocinski; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-03       Impact factor: 5.742

8.  The Cost of Hematopoietic Stem-Cell Transplantation in the United States.

Authors:  Michael S Broder; Tiffany P Quock; Eunice Chang; Sheila R Reddy; Rajni Agarwal-Hashmi; Sally Arai; Kathleen F Villa
Journal:  Am Health Drug Benefits       Date:  2017-10

9.  Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies.

Authors:  Koichi Hirabayashi; Yozo Nakazawa; Kazuo Sakashita; Takashi Kurata; Shoji Saito; Kentaro Yoshikawa; Miyuki Tanaka; Ryu Yanagisawa; Kenichi Koike
Journal:  Sci Rep       Date:  2014-11-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.